Tetraphase Pharmaceuticals, Inc. (TTPH) News
Filter TTPH News Items
TTPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TTPH News From Around the Web
Below are the latest news stories about Tetraphase Pharmaceuticals Inc that investors may wish to consider to help them evaluate TTPH as an investment opportunity.
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene TherapyThe following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (announced new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease) * Burning Rock Biotech Ltd (NASDAQ: BNR) (went public June 12) * Cardiff Oncology Inc (NASDAQ: CRDF) * ESSA Pharma Inc (NASDAQ: EPIX) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Kamada Ltd. (NASDAQ: KMDA) * Novavax, Inc. (NASDAQ: NVAX) * Passage Bio Inc... |
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value… |
La Jolla Pharma makes unsolicited bid for Tetraphase PharmaThe bidding competition for Tetraphase Pharmaceuticals (TTPH) is not over yet. La Jolla Pharmaceutical (LJPC) has submitted an unsolicited bid of $43.0M in cash plus an additional $16.0 payable under contingent value rights (CVRs).The board has determined that the offer is superior to Melinta Therapeutics' (MLNT) bid of $39.0M in... |
La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened OfferThe bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com |
Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to MelintaTetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an unsolicited proposal from La Jolla Pharmaceutical Company ("La Jolla") to acquire Tetraphase for $43.0 million in cash, plus an additional aggregate amount of $16.0 million in cash potentially payable under contingent value rights ("CVRs") to be issued in the transaction (the "La Jolla Proposal"), and that on June 21, 2020 the Board determined that the La Jolla Proposal is a "Superior Offer" under the terms of the Agreement and Plan of Merger, dated June 4, 2020, t... |
The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological AssetHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Imara Inc (NASDAQ: IMRA ) IMMURON LTD/S ADR (NASDAQ: IMRN )( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea) Inari Medical Inc (NASDAQ: NARI ) Keros Therapeutics Inc (NASDAQ: KROS ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) United Therapeutics Corporation (NASDAQ: UTHR ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 9) Applied Molecular Transport Inc (NASDAQ: AMTI ) (IPOed Friday) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Stocks In ... |
Tetraphase up 61% premarket after Melinta emerges as top bidderNano cap Tetraphase Pharmaceuticals (TTPH) is up 61% premarket on robust volume. Yesterday, initial suitor AcelRx Pharmaceuticals announced that it would not revise its latest offer for the company. Melinta Therapeutics submitted the top bid of $34M in cash plus $16M payable under a CVR.... |
Melinta Therapeutics to Acquire Tetraphase PharmaceuticalsWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced that it has entered into a definitive merger agreement with Melinta Therapeutics, Inc. (“Melinta”), pursuant to which Melinta would acquire Tetraphase, through a tender offer, for an aggregate of $39.0 million in cash, plus an additional $16.0 million in cash pot |
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo AntibioticHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Fortress Biotech (NASDAQ: FBIO ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Pliant Therapeutics Inc (NASDAQ: PLRX ) (went public Wednesday) Protara Therapeutics Inc (NASDAQ: TARA ) Qiagen NV (NYSE: QGEN ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) United Therapeutics Corporation (NASDAQ:... |
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo AntibioticHere's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Fortress Biotech (NASDAQ: FBIO) * Imara Inc (NASDAQ: IMRA) * Inari Medical Inc (NASDAQ: NARI) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * Keros Therapeutics Inc (NASDAQ: KROS) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Phathom Pharmaceuticals Inc (NASDAQ: PHAT) * Pliant Therapeutics Inc (NASDAQ: PLRX) (went public Wednesday) * Protara Therapeutics Inc (NASDAQ: TARA) * Qiagen NV (NYSE: QGEN) * Turning Point Therapeutics Inc (NASDAQ: TPTX) * Unit... |